Crossmark Global Holdings Inc. Lowers Position in Qiagen (NYSE:QGEN)

Crossmark Global Holdings Inc. lessened its stake in Qiagen (NYSE:QGEN) by 17.6% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 56,775 shares of the company’s stock after selling 12,133 shares during the quarter. Crossmark Global Holdings Inc.’s holdings in Qiagen were worth $2,587,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of the stock. GAMMA Investing LLC raised its stake in Qiagen by 806.5% during the third quarter. GAMMA Investing LLC now owns 562 shares of the company’s stock valued at $26,000 after purchasing an additional 500 shares in the last quarter. Toronto Dominion Bank purchased a new stake in Qiagen during the second quarter valued at $27,000. Massmutual Trust Co. FSB ADV raised its stake in Qiagen by 39.8% during the third quarter. Massmutual Trust Co. FSB ADV now owns 853 shares of the company’s stock valued at $39,000 after purchasing an additional 243 shares in the last quarter. CWM LLC raised its stake in Qiagen by 12.0% during the second quarter. CWM LLC now owns 2,505 shares of the company’s stock valued at $103,000 after purchasing an additional 269 shares in the last quarter. Finally, Headlands Technologies LLC raised its stake in Qiagen by 396.6% during the second quarter. Headlands Technologies LLC now owns 2,741 shares of the company’s stock valued at $113,000 after purchasing an additional 2,189 shares in the last quarter. Hedge funds and other institutional investors own 70.00% of the company’s stock.

Qiagen Trading Down 1.9 %

NYSE QGEN opened at $43.23 on Wednesday. The company’s 50-day moving average price is $43.99 and its 200-day moving average price is $43.78. The company has a current ratio of 1.77, a quick ratio of 1.46 and a debt-to-equity ratio of 0.27. The stock has a market cap of $9.87 billion, a PE ratio of 110.85, a PEG ratio of 3.28 and a beta of 0.41. Qiagen has a 12 month low of $37.90 and a 12 month high of $47.44.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the stock. HSBC downgraded shares of Qiagen from a “buy” rating to a “hold” rating and set a $49.00 price target on the stock. in a research note on Thursday, October 17th. Robert W. Baird increased their target price on shares of Qiagen from $49.00 to $52.00 and gave the company an “outperform” rating in a research note on Friday, August 2nd. Finally, Hsbc Global Res raised shares of Qiagen to a “hold” rating in a research note on Thursday, October 17th. Four equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, Qiagen presently has a consensus rating of “Moderate Buy” and an average target price of $50.88.

About Qiagen

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.